A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

A new phase 3 trial reveals that combining enzalutamide and leuprolide significantly improves overall survival for men with ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...

A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier.

A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, ...

A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay ...

Adding PARP inhibitor niraparib to standard prostate cancer treatment delays disease progression in men with certain DNA ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas") today announced final ...

The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by ...

Drugs already in use could be combined to form a two-pronged attack on advanced prostate cancer, a study suggests.

A targeted drug combination delays advanced prostate cancer in men with specific DNA repair gene mutations. A large international study led by researchers at UCL has found that a new combination of dr ...

CNN — (CNN) — President Joe Biden’s diagnosis of metastatic prostate cancer has understandably raised concerns and questions: How long has he had cancer, how will he be treated, and what is his ...